Steven Brown1, Jim Tiernan2, Katie Biggs3, Daniel Hind3, Neil Shephard3, Mike Bradburn3, Allan Wailoo3, Abualbishr Alshreef3, Lizzie Swaby3, Angus Watson4, Simon Radley5, Oliver Jones6, Paul Skaife7, Anil Agarwal8, Pasquale Giordano9, Marc Lamah10, Mark Cartmell11, Justin Davies12, Omar Faiz13, Karen Nugent14, Andrew Clarke15, Angus MacDonald16, Phillip Conaghan17, Paul Ziprin18, Rohit Makhija19. 1. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 2. Leeds Teaching Hospitals NHS Trust, Leeds, UK. 3. School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK. 4. NHS Highland, Inverness, UK. 5. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 6. Oxford University Hospitals NHS Trust, Oxford, UK. 7. Aintree University Hospital NHS Foundation Trust, Liverpool, UK. 8. North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, UK. 9. Barts Health NHS Trust, London, UK. 10. Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. 11. Northern Devon Healthcare NHS Trust, Devon, UK. 12. Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 13. North West London Hospitals NHS Trust, London, UK. 14. University Hospital Southampton NHS Foundation Trust, Southampton, UK. 15. Poole Hospital NHS Foundation Trust, Poole, UK. 16. NHS Lanarkshire, Airdrie, UK. 17. Royal Berkshire NHS Foundation Trust, Reading, UK. 18. Imperial College Healthcare NHS Trust, London, UK. 19. Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, UK.
Abstract
BACKGROUND: Optimal surgical intervention for low-grade haemorrhoids is unknown. Rubber band ligation (RBL) is probably the most common intervention. Haemorrhoidal artery ligation (HAL) is a novel alternative that may be more efficacious. OBJECTIVE: The comparison of HAL with RBL for the treatment of grade II/III haemorrhoids. DESIGN: A multicentre, parallel-group randomised controlled trial. PERSPECTIVE: UK NHS and Personal Social Services. SETTING: 17 NHS Trusts. PARTICIPANTS: Patients aged ≥ 18 years presenting with grade II/III (second- and third-degree) haemorrhoids, including those who have undergone previous RBL. INTERVENTIONS:HAL with Doppler probe compared with RBL. OUTCOMES: Primary outcome - recurrence at 1 year post procedure; secondary outcomes - recurrence at 6 weeks; haemorrhoid severity score; European Quality of Life-5 Dimensions, 5-level version (EQ-5D-5L); Vaizey incontinence score; pain assessment; complications; and cost-effectiveness. RESULTS: A total of 370 participants entered the trial. At 1 year post procedure, 30% of the HAL group had evidence of recurrence compared with 49% after RBL [adjusted odds ratio (OR) = 2.23, 95% confidence interval (CI) 1.42 to 3.51; p = 0.0005]. The main reason for the difference was the number of extra procedures required to achieve improvement/cure. If a single HAL is compared with multiple RBLs then only 37.5% recurred in the RBL arm (adjusted OR 1.35, 95% CI 0.85 to 2.15; p = 0.20). Persistence of significant symptoms at 6 weeks was lower in both arms than at 1 year (9% HAL and 29% RBL), suggesting significant deterioration in both groups over the year. Symptom score, EQ-5D-5L and Vaizey score improved in both groups compared with baseline, but there was no difference between interventions. Pain was less severe and of shorter duration in the RBL group; most of the HAL group who had pain had mild to moderate pain, resolving by 3 weeks. Complications were low frequency and not significantly different between groups. It appeared that HAL was not cost-effective compared with RBL. In the base-case analysis, the difference in mean total costs was £1027 higher for HAL. Quality-adjusted life-years (QALYs) were higher for HAL; however, the difference was very small (0.01) resulting in an incremental cost-effectiveness ratio of £104,427 per additional QALY. CONCLUSIONS: At 1 year, although HAL resulted in fewer recurrences, recurrence was similar to repeat RBL. Symptom scores, complications, EQ-5D-5L and continence score were no different, and patients had more pain in the early postoperative period after HAL. HAL is more expensive and unlikely to be cost-effective in terms of incremental cost per QALY. LIMITATIONS: Blinding of participants and site staff was not possible. FUTURE WORK: The incidence of recurrence may continue to increase with time. Further follow-up would add to the evidence regarding long-term clinical effectiveness and cost-effectiveness. The polysymptomatic nature of haemorrhoidal disease requires a validated scoring system, and the data from this trial will allow further assessment of validity of such a system. These data add to the literature regarding treatment of grade II/III haemorrhoids. The results dovetail with results from the eTHoS study [Watson AJM, Hudson J, Wood J, Kilonzo M, Brown SR, McDonald A, et al. Comparison of stapled haemorrhoidopexy with traditional excisional surgery for haemorrhoidal disease (eTHoS): a pragmatic, multicentre, randomised controlled trial. Lancet 2016, in press.] comparing stapled haemorrhoidectomy with excisional haemorrhoidectomy. Combined results will allow expansion of analysis, allowing surgeons to tailor their treatment options to individual patients. TRIAL REGISTRATION: Current Controlled Trials ISRCTN41394716. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 88. See the NIHR Journals Library website for further project information.
RCT Entities:
BACKGROUND: Optimal surgical intervention for low-grade haemorrhoids is unknown. Rubber band ligation (RBL) is probably the most common intervention. Haemorrhoidal artery ligation (HAL) is a novel alternative that may be more efficacious. OBJECTIVE: The comparison of HAL with RBL for the treatment of grade II/III haemorrhoids. DESIGN: A multicentre, parallel-group randomised controlled trial. PERSPECTIVE: UK NHS and Personal Social Services. SETTING: 17 NHS Trusts. PARTICIPANTS: Patients aged ≥ 18 years presenting with grade II/III (second- and third-degree) haemorrhoids, including those who have undergone previous RBL. INTERVENTIONS:HAL with Doppler probe compared with RBL. OUTCOMES: Primary outcome - recurrence at 1 year post procedure; secondary outcomes - recurrence at 6 weeks; haemorrhoid severity score; European Quality of Life-5 Dimensions, 5-level version (EQ-5D-5L); Vaizey incontinence score; pain assessment; complications; and cost-effectiveness. RESULTS: A total of 370 participants entered the trial. At 1 year post procedure, 30% of the HAL group had evidence of recurrence compared with 49% after RBL [adjusted odds ratio (OR) = 2.23, 95% confidence interval (CI) 1.42 to 3.51; p = 0.0005]. The main reason for the difference was the number of extra procedures required to achieve improvement/cure. If a single HAL is compared with multiple RBLs then only 37.5% recurred in the RBL arm (adjusted OR 1.35, 95% CI 0.85 to 2.15; p = 0.20). Persistence of significant symptoms at 6 weeks was lower in both arms than at 1 year (9% HAL and 29% RBL), suggesting significant deterioration in both groups over the year. Symptom score, EQ-5D-5L and Vaizey score improved in both groups compared with baseline, but there was no difference between interventions. Pain was less severe and of shorter duration in the RBL group; most of the HAL group who had pain had mild to moderate pain, resolving by 3 weeks. Complications were low frequency and not significantly different between groups. It appeared that HAL was not cost-effective compared with RBL. In the base-case analysis, the difference in mean total costs was £1027 higher for HAL. Quality-adjusted life-years (QALYs) were higher for HAL; however, the difference was very small (0.01) resulting in an incremental cost-effectiveness ratio of £104,427 per additional QALY. CONCLUSIONS: At 1 year, although HAL resulted in fewer recurrences, recurrence was similar to repeat RBL. Symptom scores, complications, EQ-5D-5L and continence score were no different, and patients had more pain in the early postoperative period after HAL. HAL is more expensive and unlikely to be cost-effective in terms of incremental cost per QALY. LIMITATIONS: Blinding of participants and site staff was not possible. FUTURE WORK: The incidence of recurrence may continue to increase with time. Further follow-up would add to the evidence regarding long-term clinical effectiveness and cost-effectiveness. The polysymptomatic nature of haemorrhoidal disease requires a validated scoring system, and the data from this trial will allow further assessment of validity of such a system. These data add to the literature regarding treatment of grade II/III haemorrhoids. The results dovetail with results from the eTHoS study [Watson AJM, Hudson J, Wood J, Kilonzo M, Brown SR, McDonald A, et al. Comparison of stapled haemorrhoidopexy with traditional excisional surgery for haemorrhoidal disease (eTHoS): a pragmatic, multicentre, randomised controlled trial. Lancet 2016, in press.] comparing stapled haemorrhoidectomy with excisional haemorrhoidectomy. Combined results will allow expansion of analysis, allowing surgeons to tailor their treatment options to individual patients. TRIAL REGISTRATION: Current Controlled Trials ISRCTN41394716. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 88. See the NIHR Journals Library website for further project information.
Authors: Aurelien Venara; Juliette Podevin; Philippe Godeberge; Yann Redon; Marie-Line Barussaud; Igor Sielezneff; Michel Queralto; Cecile Bourbao; Anne Chiffoleau; Paul A Lehur Journal: Int J Colorectal Dis Date: 2018-05-28 Impact factor: 2.571
Authors: A Sturiale; B Fabiani; C Menconi; D Cafaro; F Fusco; G Bellio; M Schiano di Visconte; G Naldini Journal: Tech Coloproctol Date: 2018-10-04 Impact factor: 3.781
Authors: R R van Tol; E van Zwietering; J Kleijnen; J Melenhorst; L P S Stassen; C D Dirksen; S O Breukink Journal: Int J Colorectal Dis Date: 2018-04-22 Impact factor: 2.571
Authors: Robin R van Tol; Marieke P A Bruijnen; Jarno Melenhorst; Sander M J van Kuijk; Laurents P S Stassen; Stéphanie O Breukink Journal: Int J Colorectal Dis Date: 2018-03-15 Impact factor: 2.571
Authors: Donatas Danys; Julius Pacevicius; Gabija Makunaite; Rolandas Palubeckas; Antanas Mainelis; Narimantas Markevicius; Kestutis Strupas; Tomas Poskus Journal: Open Med (Wars) Date: 2020-03-08